Item 2.02 Results of Operations and Financial Condition.

Repare Therapeutics Inc. (the "Company") intends to share with investors the amount of cash, cash equivalents, restricted cash and marketable securities it had on hand as of December 31, 2021. Although the Company has not finalized its financial results for the twelve months ended December 31, 2021, the Company preliminarily estimates that its cash, cash equivalents, restricted cash and marketable securities as of December 31, 2021 was approximately $341.7 million.

The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2021 and its results of operations for the three months and year ended December 31, 2021. The audit of the Company's financial statements for the year ended December 31, 2021 is ongoing. The Company's actual consolidated cash, cash equivalents, restricted cash and marketable securities as of December 31, 2021 may differ from these estimates due to the completion of the Company's year-end closing and auditing procedures.

The information in this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses